CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
B 细胞恶性肿瘤 CAR-T 细胞（CAR-T 细胞）治疗后的感染并发症与预防策略
英文原题：Infectious Complications and Preventative Strategies following Chimeric Antigen Receptor T-cells (CAR-T cells) Therapy for B-Cell Malignancies.
查看英文原题
Infectious Complications and Preventative Strategies following Chimeric Antigen Receptor T-cells (CAR-T cells) Therapy for B-Cell Malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
目前已有几种CAR-T 细胞构建体（CAR-T 细胞）获批用于治疗B细胞恶性肿瘤，包括非霍奇金淋巴瘤和急性淋巴细胞白血病。此外，多种其他产品正在研究开发中，用于治疗其他血液系统恶性肿瘤和实体癌。接受CAR-T 细胞治疗的患者感染并发症风险增加，导致这些患者发病率升高和死亡率更差。在这篇综述中，我们讨论了关于CAR-T 细胞输注后早期和晚期患者感染发生率和类型的文献。此外，我们总结了当前关于CAR-T 细胞输注后病毒、细菌和真菌感染预防的文献，以及包括静脉注射免疫球蛋白和髓系生长因子在内的预防和支持措施的效用。
展开英文摘要原文
Several chimeric antigen receptor T-cell constructs (CAR-T cells) are currently approved for the treatment of B-cell malignancies, including non-Hodgkin lymphoma and acute lymphoblastic leukemia.
Additionally, multiple other products are being investigated and developed for other hematological malignancies and solid cancers. Patients receiving CAR-T cells are at increased risk of infectious complications that lead to increased morbidity and inferior mortality in these patients. In this review, we discuss the literature on the incidence and types of infection in patients in the early and late-phase after CAR-T cells infusion.
Additionally, we summarize the current literature on prophylaxis against viral, bacterial, and fungal infections after CAR-T cells infusion and the utility of preventative and supportive measures including intravenous immunoglobulins and myeloid growth factors.
论文信息
- 作者
- Haroon A、Muhsen IN、Abid MB、Albabtain A、Alahmari A、Ahmed SO、Fakih RE、Aljurf M
- 单位
- Oncology Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.Saudi Arabia
- 文献类型
- 综述
- 期刊
- Hematology/oncology and stem cell therapy2022 Nov 25
- 原文标识
- PubMed 36633965 · DOI 10.56875/2589-0646.1049